1. Home
  2. MG vs MYGN Comparison

MG vs MYGN Comparison

Compare MG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mistras Group Inc

MG

Mistras Group Inc

HOLD

Current Price

$14.16

Market Cap

481.7M

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.66

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MG
MYGN
Founded
1978
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
481.7M
481.6M
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
MG
MYGN
Price
$14.16
$4.66
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$7.64
AVG Volume (30 Days)
151.8K
1.5M
Earning Date
06-10-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.53
N/A
Revenue
$700,970,000.00
$771,400,000.00
Revenue This Year
$5.23
$7.19
Revenue Next Year
$3.13
$5.64
P/E Ratio
$26.91
N/A
Revenue Growth
N/A
2.33
52 Week Low
$7.06
$3.76
52 Week High
$15.84
$10.32

Technical Indicators

Market Signals
Indicator
MG
MYGN
Relative Strength Index (RSI) 42.92 41.35
Support Level $13.80 $3.93
Resistance Level $14.96 $5.63
Average True Range (ATR) 0.76 0.42
MACD -0.16 0.04
Stochastic Oscillator 40.07 21.43

Price Performance

Historical Comparison
MG
MYGN

About MG Mistras Group Inc

MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: